natgillin/translations-raw huggingface dataset:
with the proviso that when R3 is an alkyl group having 1 to 6 carbon atoms substituted with a hydroxyl group and when R4 is a carboxyl group, then R3 and R4 may optionally be fused to form a lactone ring; 
uz uvjet da kada R, je alkilna skupina koja ima 1 do 6 ugljikovih atoma supstituiranih s hidroksilnom skupinom i kada R, je karboksilna skupina, tada Rs i R, mogu proizvoljno biti kondenzirani tako da tvore laktonski prsten;
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
A composition as claimed in Claim 8, wherein the cyclodextrin is 2-hydroxypropyl-B-cyclodextrin and is present at a concentration of 25%, and the buffer is 10 mM phosphate at pH 7.4. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin 2-hidroksipropil-f-ciklodekstrin i je prisutan u koncentraciji od 25%, a puferje 10 mM fosfat s pH 7,4.
two R6 substituents are taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from one O, one S, and up to 2 N, wherein up to 2 carbon atom ring members are independently selected from C(=O) and C(=S) and the sulfur atom ring member is selected from S, S(O) or S(O)2, said ring optionally substituted with up to 4 substituents independently selected from the group consisting of halogen, cyano and C1-C4 alkyl; 
R je3- do 10-člani prsten ili 7- do 11-člani sustav prstena, pri čemu svaki prsten ili sustav prstena sadrži članove prstena koji su izabrani od atoma ugljika i do 4 heteroatoma nezavisno izabrana od maksimalno 2 O, maksimalno 2 S i maksimalno 4 N, gdje su maksimalno 3 atoma ugljika koji su članovi prstena nezavisno izabrani od C(=0) 1 C(=S) i članovi prstena atomi sumpora su nezavisno izabrani od S(=0),(SNR*),, pri čemu je svaki prsten ili sustav prstena izborno supstituiran sa do 5 supstituenata nezavisno izabrana od R'%
"heteroaryl" refers to a 4-, 5-, 6-, or 7-membered monocyclic, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic unsaturated ring or ring system - carrying the highest possible number of conjugated double bonds in the ring(s), which contain at least one heteroatom selected from N, O and S, wherein the N and S can also optionally be oxidized to various oxidation states; 
-člani, 8-člani, 9-člani, 10-člani, 11-člani ili 12-člani biciklički prsten ili 10-člani, -člani, 12-člani, 13-člani, 14-člani ili 15-člani triciklički prsten koji je nezasićen, ili se isto odnosi i na sustav prstena – noseći pritom najveći mogući broj konjugiranih dvostrukih veza u prstenu ili prstenovima, koji sadrže jedan heteroatom odabran od N, O i S, pri čemu N i S također mogu biti oksidirani do različitih oksidacijskih stanja;
The composition of claim 3, wherein the second therapeutic agent is selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir potassium, saquinavir, lopinavir, nevirapine, emtricitabine, abacavir, lamivudine, zidovudine, maraviroc, stavudine, darunavir, fosamprenavir, vicriviroc, a pharmaceutically acceptable salt of any of the foregoing, and combinations thereof. 
Spoj ili kompozicija prema zahtjevu 16, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir dizoproksila, nelfinavir mesilata, amprenavira, kalij raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicriviroca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
In vivo Experiments 
In vivo eksperimenti
A cocktail of nucleic acid molecules according to claim 8 or 9 wherein the at least first and second different nucleic acid molecules comprise a cocktail of nucleic acid molecules selected from the group consisting of: 
Koktel molekula nukleinske kiseline koji sadrži najmanje dvije različite molekule nukleinske kiseline, gdje najmanje dvije različite molekule nukleinske kiseline sadrže koktel molekula nukleinske kiseline odabran iz grupe koja se sastoji od:
drying the wet web (154) to form the absorbent cellulosic sheet (10), wherein the papermaking furnish is selected and the steps of belt-creping, applying the vacuum, and drying are controlled such that the sheet (10) has: 
(d) sušenjem strukture (154), pri čemu je oprema izrade papira odabrana, a koraci krepiranja remenom i sušenja su kontrolirani tako da osušena struktura ima:
In other embodiments, the mobile mass has more than one angled surface, such as first and second angled surfaces, the first angled surface contacting a surface of the mobile bolt immediately after firing and/or in the cocked or loaded position. 
Vatreno oružje iz patentnog zahtjeva 1 ili 2, pri čemu pomična masa (34) ima prvu i drugu kutnu površinu, prva kutna površina dodiruje površinu pomičnog zasuna (22) odmah nakon paljbe.
The recommended levels of dopants for ZrO2 are Y2O3 (1-5%), MgO (1-5%), CaO (1-10%), and CeO2 (1-6%), more specifically about 1-2%. 
Preporučene razine sredstva za dopiranje za ZrO, su YO; (1-5%), MgO (1-5%), CaO (1-10%) i CeO, (1-6%), specifičnije oko 1-2%.
The firearm of claim 1, wherein the mobile mass has first and second angled surfaces, the first angled surface contacting a surface of the mobile bolt immediately after firing. 
Vatreno oružje iz patentnog zahtjeva 1 ili 2, pri čemu pomična masa (34) ima prvu i drugu kutnu površinu, prva kutna površina dodiruje površinu pomičnog zasuna (22) odmah nakon paljbe.
The C2-10 dialkylamino group represents an amino group substituted by two C1-5 alkyl groups, for example, dimethylamino group, ethylmethylamino group, diethylamino group, methylpropylamino group and diisopropylamino group; 
C2.10 dialkilamino skupina predstavlja amino skupinu supstituiranu s dvije C,.5 alkilne skupine, primjerice dimetilamino skupinu, etilmetilamino skupinu, dietilamino skupinu, metilpropilamino skupinu i diizopropilamino skupinu.
The compound according to any one of the above-mentioned [1] to [3] or a salt thereof, wherein R2 represents a C1-6 alkyl group substituted by one or two COOH. 
Spoj prema zahtjevu 1 ili njegova sol, naznačen time što R* predstavlja C,. alkilnu skupinu supstituiranu jednom ili dvjema skupinama COOH.
The pharmaceutical formulation of claim 11, wherein at least 96% of native form of said antibody is recovered after nine months of storage at 5° C., as determined by size exclusion-high performance liquid chromatography (SE-HPLC). The pharmaceutical formulation of claim 3, wherein the formulation exhibits a viscosity of less than about 15 cPoise. 
Farmaceutski pripravak prema patentnom zahtjevu 1 ili 2, naznačen time, što se najmanje 96 % izvornog oblika spomenutog antitijela dobiva nakon devetomjesečne pohrane na temperaturi od 5 "C, što se utvrđuje pomoću visokoučinkovite tekućinske kromatografije isključivanja po veličini (SE-HPLC).
The antibody of any one of claims 1 to 4 for the use of claim 7, wherein the use further comprises administering a second therapeutic agent for treating or preventing acute lung injury. 
Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4 za uporabu prema patentnom zahtjevu 7, naznačen time, da se uporaba dalje sastoji od primjene drugog terapijskog sredstva za liječenje ili sprječavanje akutne ozljede pluća.
The multispecific antigen-binding molecule of claim 3, wherein the first and second polypeptides comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region, and wherein the third polypeptide and the fourth polypeptide are a commonly shared L chain. 
prvi i drugi polipeptid obuhvaćaju konstantno područje H-lanca protutijela, a treći i četvrti polipeptid obuhvaćaju konstantno područje L-lanca protutijela, te su pritom treći polipeptid i četvrti polipeptid zajednički korišten L-lanac.
In one embodiment of the invention there is provided a process comprising the step of monitoring the temperature in the poultry shed and controlling the temperature of the environment in the poultry shed by regulating the flow of heated liquid to the radiator element. 
Postupak prema zahtjevima 5 do 9 koji obuhvaća korak praćenja temperature u nastambi za perad i kontrole okolne temperature u nastambi za perad tako što se regulira protok zagrijane tekućine do radijatora.
Thus for a typical adult patient, individual tablets or capsules are likely to contain from 1 to 10 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. 
Tako, za tipičnog odraslog pacijenta, individualno tablete ili kapsule će vjerojatno sadržavati od 1 do 10 mg aktivnog spoja u prikladnom farmaceutski prihvatljivom puniocu ili nosaču.
The nail is formed in layers analogous to the formation of scales in the skin: the thin lamellae then break off. 
Nokat nastaje u slojevima analogno nastanku slojeva kože: potom se tanke lamele odvajaju.
The use of a compressor in the dispenser makes this relatively complex, whilst the compressor can give rise to vibration and an increased noise level. 
Korištenje kompresora u raspršivaču ga čini relativno kompleksnim, dok sam kompresor može izazvati povećane vibracije i podići razinu buke.
The safety anchorage of the embodiment of FIG. 
Datum podnošenja europske prijave patenta:
A compound according to claim 6 selected from 
Spoj u skladu sa patentnim zahtjevom 6 odabrano od
the concentration of the recovered autoactivating proelastase protein in the solution is less than 10 mg/ml, less than 5 mg/ml, less than 2 mg/ml, less than 1 mg/ml, less than 0.5 mg/ml, less than 0.25 mg/ml and/or at least 0.1mg/ml or at least 0.2 mg/ml; and/or 
koncentracija oporavljenog autoaktivacijskog proteina proelastaze u otopini je manja od 10 mg/ml, manja od 5 mg/ml, manja od 2 mg/ml, manja od 1 mg/ml, manja od 0,5 mg/ml, manja od 0,25 mg/ml i/ili najmanja od 0,1 mg/ml ili najmanja od 0,2 mg/ml; i/ili
The coating formulation according to claim 1, which is thixotropic. A material coated with the coating formulation according to claim 1, wherein the material is selected from the group consisting of paper, board, wall-paper, wood, wood composites, lake board, plastics, foil, concrete, coated or uncoated rendering, plaster, metals, ceramics, stone, brickstone and glass. 
Materijal koji sadrži pripravak prema bilo kojem od zahtjeva 1 do 19, naznačen time da se materijal poželjno se bira iz skupine koju čine papir, karton, tapete, drvo, drveni kompoziti kao ploče od usinjenog drva, plastika, folija, beton, obložena ili neobložena žbuka, žbuka, metali, keramika, kamen, kamene cigle i staklo.
a group of formula (i) a group of formula (ii): 
(4) skupina formule (1) ili (5) skupina formule (11):
Molecular sieves (6.1g, 15wt%/g) were added to the solution and stirring was begun. 
Molekulska sita (6.1 g, 15 masenih % g) bila su dodana otopini i započelo je miješanje.
replacement of an endogenous rat nucleic acid sequence with a homologous or an orthologous nucleic acid sequence; 
(a) zamjenu sekvence endogene nukleinske kiseline štakora s homolognom ili ortolognom sekvencom nukleinske kiseline;
a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9. 
(c) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:15 1 varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:9;
The method according to claim 4, wherein transfection is carried out with a total DNA amount of at least 1.5 µg/106 cells. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se transficiranje provodi ukupnom količinom DNA od najmanje 1,5 ug/ 10" stanica.
The technology relates to detecting the wiring phase of an unknown phase voltage relative to a reference phase voltage in an electric power distribution system having a polyphase power line. In order to reliably detect the wiring phase at the remote location relative to a reference wiring phase even if the remote location is at a larger distance from the reference location, at least one relay location is arranged between the reference location and the remote location and connected to the wiring phase of the polyphase power line. 
Postupak za detekciju faznog vodiča (R; $; T) na udaljenoj lokaciji u odnosu prema referentnom faznom vodiču (R) na referentnoj lokaciji u sustavu distribucije električne energije koji sadrži jednostruku liniju ili polifaznu liniju vodiča (R, S, T, N), naznačen time, da postupak obuhvaća korake: - < povezivanje barem jedne relejne lokacije na fazni napon vodiča od spomenute polifazne linije na lokaciji između spomenute referentne lokacije i spomenute udaljene lokacije,
When the active compound is ET-743, the ratio (w/w) of ET-743 to bulking agent is typically from about 1:100 to about 1:1500, preferably from about 1:200 to about 1:800, more preferably from about 1:250 to about 1:600, and even more preferably about 1:400. 
Kada je aktivni spoj ET-743, odnos (mas./mas.) ET-743 prema sredstvu za punjenje je obično od oko 1:100 do oko 1:1500. poželjno od oko 1:200 do oko 1:800, poželjnije od oko 1:250 do oko 1:600, a čak poželjnije oko 1:400.
the first and second polypeptides comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region, and wherein the third polypeptide and the fourth polypeptide are a commonly shared L chain. 
HR P20180421 T1 prvi i drugi polipeptid obuhvaćaju konstantno područje H-lanca protutijela, a treći i četvrti polipeptid obuhvaćaju konstantno područje L-lanca protutijela, te su pritom treći polipeptid i četvrti polipeptid zajednički korišten L-lanac.
reacting a boronic acid or ester having the formula: wherein Y is OR20, R20 is hydrogen or C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, or two OR20 units can be taken together to form a 5-member to 7-member C3-C10 cyclic ester, with a 3,5-dihalo-2-cyanopyridine having the formula: each Z is independently chloro or bromo, in the presence of a catalyst, to form a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine having the formula: 
A) reakciju boronske kiseline ili estera formule: RI gdje Y jest OR", R" je vodik ili C,-C4 linearni, C3-C4 razgranati, ili C3-C4 ciklički alkil, ili dvije OR" jedinice mogu biti uzete zajedno da formiraju 5- do 7-eročlani C3-C,g ciklički ester, s 3,5-dihalo-2-cijanopiridinom formule:
The system according to any one of the preceding claims, wherein the system further comprises one or more additional modules selected from the group consisting of a loading module, gasification module, cleaning module, and water-gas-shift and hydrogen separation module. 
Sustav prema bilo kojem od prethodnih zahtjeva, naznačen time da sustav nadalje sadrži jedan 1li više dodatnih modula odabranih iz skupine koja se sastoji od modula za punjenje, modula za rasplinjavanje, modula za čišćenje, 1 modula za dobivanje dodatne količine vodika i modula za odvajanje vodika.
The composition for use_of any one of claims 1-13, wherein the first heterologous antigen and the second heterologous antigen are the same antigen. 
Pripravak za upotrebu u skladu s patentnim zahtjevom13 ili 14, naznačen time, da su prvi heterologni antigen i drugi heterologni antigen isti antigen.
The compound or a pharmaceutically acceptable salt thereof for use according to claim 4, wherein said B-related pathology is Alzheimer's Disease. 
Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 4, naznačen time da navedena AB-povezana patologija je Alzheimerova bolest.
The process according to claim 12, in which at least a portion of the stream comprising middle distillate base is recycled to the separation c). 
Postupak prema jednom od patentnih zahtjeva 1 do 11, naznačen time što se najmanje dio srednje destilatne baze reciklira u stupnju razdvajanja c).
When tensioning is effected, the container 13 is moved axially downwards until the container 13 assumes a final position in the tensioned state, as indicated in Figure 5. 
Kad je postignuto naprezanje, spremnik se pomakne aksijalno prema dolje sve dok spremnik 13 zauzme svoj krajnji položaj u napregnutom stanju, kako je prikazano na slici 5.
The absorbent product for personal care of claim 2 wherein the weight ratio of citric acid to carboxymethylcellulose is about 1% to about 5%. 
Polimerni hidrogel u skladu s patentnim zahtjevom 4, naznačen time da je težinski omjer karboksimetilceluloze naspram hidroksietilceluloze u vodenoj otopini od 2:1 do 5:1.
For the gluing, said patent suggests adhesives such as epoxy resin, phenolic resin and resorcinol resin. 
Za lijepljenje, navedeni patent sugerira takvo ljepilo kao što je epoksidna smola, fenolna smola i resorcinolna smola.
The method of claim 12, wherein the infill material comprises sand, crushed stone, gravel, or mixtures thereof. The method of claim 12, wherein the second geocell layer or second geogrid layer is spaced apart from the first geocell layer by a distance of zero to about 500 mm. 
Postupak prema zahtjevu 14, naznačen time što je drugi sloj geoćelije (120) ili drugi sloj geomreže (130) odmaknut od prvog sloja geoćelije (80) na udaljenost od nula do oko 500 mm.
wherein is selected from the group consisting of C1-4alkyl and C3-10cycloalkyl; 
je odabran iz skupine koju čine C1-4alkil i C3-10cikloalkil; m je 2
the use according to (8), wherein the disease to be treated is selected from lymphoma, anaplastic large-cell lymphoma, non-Hodgkin's lymphomas, inflammatory myofibroblastic tumors and neuroblastomas; 
Uporaba prema zahtjevu 8, naznačena time, da se proliferativna bolest koja se treba liječiti odabire od tumora sljedećih vrsta: dojke, renalni, prostate, kolorektalni, tiroidni, jajnika, gušterače, neuronalni, plućni, materični i gastro-intestinalni tumori kao i osteosarkomi i melanomi.
The process of claim 2, wherein PG is methoxy formyl. 
formil, f-butoksi formil, i-propoksi formil ili metoksi formil.
The composition of claim 3, wherein said PEG-IFN-B is present at a concentration of 0.044 mg/ml, 0.055 mg/ml or 0.110 mg/ml. 
Pripravak prema zahtjevu 3, naznačen time da navedeni PEG-I FN- B je prisutan u koncentraciji od 0.044 mg/ml, 0.055 mg/ml ili 0.110 mg/ml.
Method according to claim 12, characterised in that glue is sprayed onto the wrapper (2) to form dots of glue, preferably at least at the ends of the wrapper (2). 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se ljepilo nanese sprejanjem na omot (2), kako bi se stvorile točke ljepila, poželjno barem na krajevima omota (2).
a lateral opening (3) provided in said tubular body (2) between said upstream end (2a) and said downstream end (2b) to define a lateral conduit in said device, in fluid communication with said axial conduit; 
– bočni otvor (3), koji se nalazi u navedenom cjevastom tijelu (2) između navedenog uzvodnog kraja (2a) i navedenog nizvodnog kraja (2b), koji omeđuje bočni vod u navedenom uređaju, u fluidnoj komunikaciji s navedenim aksijalnom vodom;
A method for the manufacture of Compound I having the formula defined in claim 1, comprising a step wherein Compound I is converted to a crystalline free base of Compound I. 
Postupak proizvodnje Spoja I čija je formula definirana u zahtjevu obuhvaća korak gdje se Spoj I pretvara u kristaličnu slobodnu bazu Spoja I.
is phenyl substituted by OCF3 or SCF3; R9, R10 and R11 either, independently of one another, is hydrogen, Cl, Br or methyl; 
R;je feml supstituiran s OCF; ili SCF3; bilo koji od Ro, Ri91 R11, međusobno neovisno, predstavlja vodik, Cl, Br ili metil;
R' and R" each independently represent a hydrogen atom, a hydroxyl group, a C1-C4 alkoxy group or a linear or branched C1-C4 alkyl group. 
R' i R'' svaki zasebno predstavljaju atom vodika, hidroksilnu grupu, C1-C4 alkoksi grupu ili linearnu ili razgranatu C1-C4 alkilnu grupu.
In other embodiments, a class of aptamers characterized by having high affinity for their corresponding target molecules and slow dissociation rates (t1/2) from a non-covalent complex of the aptamer and target is provided. 
Ne-kovalentni kompleks prema zahtjevu 6, naznačen time, da je brzina razdruživanja (ti/2) aptamera iz ciljane molekule, veća ili jednaka vremenu od 30 minuta.
More specifically, Figure 1 shows a container 101 engaged to a blender base 100 and a blender container 106. 
Preciznije, Slika 1 prikazuje posudu 101 postavljenu na postolje mješalice 100 i posudu mješalice 106.
The heterologous fusion protein of claim 1 wherein the heterologous fusion protein is selected from: 
Heterologni fuzijski protein u skladu s patentnim zahtjevom 7, naznačen time što fuzijski protein je dez-K oblik Gly8-Glu22-Gly36-GLP-1 (7-37)-1L-IgG4 (S228P, F234A, L235A).
The process of claim 1, wherein R1 is selected from acetyl, trifluoroacetyl, phthalimidyl, benzyl, triphenylmethyl, benzylidenyl, p-toluenesulfonyl, p-methoxybenzyl, tertbutyloxycarbonyl, 9-fluorenylmethyl oxycarbonyl and carbobenzyloxy. The process of claim 1, wherein the metalating agent is an organometal compound. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da (a) R1 je amino zaštitna skupina ili (b) R1 je amino zaštitna skupina koja je odabrana od acetila, trifluoroacetila, ftalimidila, benzila, trifenilmetila, benzilidenila, p-toluensulfonila, p-metoksibenzila, tertbutiloksikarbonila, 9-fluorenilmetiloksikarbonila i karbobenziloksi.
On the other hand, the closure force, i.e. the force with which the mobile brewing head support 7 will approach the lower frame 6 in the final phase and eventually abut against it, is much higher in this final phase of the approaching closing movement when compared to the initial stage as shown in Fig. 3. 
S druge strana, sila zatvaranja, to jest sila s kojom će se nosač pomične glave za pripremanje napitka 7 približavati donjem okviru 6 u konačnoj fazi i eventualno se nasloniti na njega, je mnogo veća u toj krajnjoj fazi približavanja kretanja zatvaranja, kada se usporedi s početnim položajem kao što je to prikazano na slici Da
The method of one of the claims 1 to 6, wherein: the cellulosic biomass comprises bagasse, palm fronds, or empty fruit bunches; and ii) the unenriched renewable fuel oil has a solids content of less than 0.5 wt.% and an ash content of less than 0.1 wt.%. 
Postupak prema jednom od zahtjeva 1 do 6, naznačen time što: 1) celulozna biomasa sadrži otpatke šećerne trske, palmino lišće ili prazne voćne grozdove; 1 1i) neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt. % i sadržaj pepela od manje od 0,1 wt.
A combination comprising a compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents. 
7. < Kombinacija, naznačena time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 5 ili njegovu farmaceutski prihvatljivu sol te jedno ili više dodatnih terapeutski sudjelatnih sredstava.